Chargement en cours...
The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
BACKGROUND: A phase 2 trial has suggested that treatment with the melanocortin-4 receptor (MC4R) agonist setmelanotide is associated with a decrease in hunger and weight-related outcomes in participants with Bardet-Biedl syndrome (BBS) and Alström syndrome. Here, we present the study design of an on...
Enregistré dans:
| Publié dans: | Contemp Clin Trials Commun |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8114053/ https://ncbi.nlm.nih.gov/pubmed/34013094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2021.100780 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|